Showing results (721-730 of 794) with videos related to
Sort By:
Pageof 80
Journal of Medicinal Chemistry|November 8, 2022
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation RatesMichael Miller, Thomas Rossetti, Jacob Ferreira, et al.Circulation|November 12, 2019
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United StatesDeepak L Bhatt, Michael Miller, Eliot A Brinton, et al.Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.Bioorganic & Medicinal Chemistry Letters|February 3, 2005
Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butaneShrenik K Shah, Natalie Chen, Ravindra N Guthikonda, et al.The Journal of Bone and Joint Surgery. American Volume|May 16, 2023
The Microbiome of Osteoarthritic Hip and Knee Joints: A Prospective Multicenter InvestigationKaran Goswami, Samuel Clarkson, Craig Tipton, et al.Journal of the American Heart Association|March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCIBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.Circulation|November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization AnalysesBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.The Journal of Pharmacology and Experimental Therapeutics|September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew J Fell, Christian Mirescu, Kallol Basu, et al.Pageof 80